Reading TFX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TFX free→Reading TFX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TFX free→QuarterlyIQ Insights · TFX
The full factor breakdown (the numbers behind each rank). The overview page shows the same reads in short form; this is the depth.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted -1.18x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
5 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
Not investment advice. As of 2026-06-12.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $1.29 → $1.27 (-1.5% / 30d). 4 raised, 6 cut, 11 covering analysts.
1 upgrade, 0 downgrades / 30d, 0 maintained. 33% of analysts rate Buy.
1 PT revisions / 30d. Avg target 23.2% above current price.
0 positive, 1 negative / 30d. See F4 management tile for the event list.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-12.